Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from barrett's esophagus: Results from biomarkers and genetic variants

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Takata, Yumie ^a   Kristal, Alan R ^a   Santella, Regina M ^b   King, Irena B ^a,c   Duggan, David J ^d   Lampe, Johanna W ^a   Rayman, Margaret P ^e   Blount, Patricia L ^a   Reid, Brian J ^a   Vaughan, Thomas L ^a   Peters, Ulrike ^a  

^a USA   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 3; SELENIUM; SELENOENZYME DERIVATIVE; SELENOPROTEIN P; UNCLASSIFIED DRUG; GLUTATHIONE PEROXIDASE; GPX3 PROTEIN, HUMAN; SELENOPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BARRETT ESOPHAGUS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DNA CONTENT; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE; GENETIC VARIABILITY; GPX1 GENE; GPX2 GENE; GPX3 GENE; GPX4 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEPP1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPLOIDY; ADENOCARCINOMA; CLINICAL TRIAL; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BARRETT ESOPHAGUS; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SELENIUM; SELENOPROTEINS;

EID: 84862013854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038612     Document Type: Article

References (48)

1. Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, et al. (1994) Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res 54: 2029s-2031s.
2. Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, et al. (1994) Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 3: 161-166.
3. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, et al. (1993) Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85: 1492-1498.
4. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, et al. (2000) Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 92: 1753-1763.
5. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963.
6. Krishnaswamy K, Prasad MP, Krishna TP, Pasricha S, (1993) A case control study of selenium in cancer. Indian J Med Res 98: 124-128.
7. Ujiie S, Kikuchi H, (2002) The relation between serum selenium value and cancer in Miyagi, Japan: 5-year follow up study. Tohoku J Exp Med 196: 99-109.
8. Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, et al. (2007) A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 28: 1323-1328.
9. Reid BJ, Li X, Galipeau PC, Vaughan TL, (2010) Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 10: 87-101.
10. Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, et al. (2003) Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst 95: 750-757.
11. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4: e67.
12. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ, (2001) Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96: 3071-3083.
13. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS, (2000) Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95: 1669-1676.
14. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, et al. (2000) Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 132: 612-620.
15. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6: 945-952.
16. Ericson SP, McHalsky ML, Rabinow BE, Kronholm KG, Arceo CS, et al. (1986) Sampling and analysis techniques for monitoring serum for trace elements. Clin Chem 32: 1350-1356.
17. Paglia DE, Valentine WN, (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169.
18. Takata Y, King IB, Lampe JW, Burk RF, Hill KE, et al. (2012) Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans. J Nutr. 142: 419-426.
19. Agarwal R, Chase SD, (2002) Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 775: 121-126.
20. Peng T, Li LQ, Peng MH, Liu ZM, Liu TW, et al. (2007) Is correction for protein concentration appropriate for protein adduct dosimetry? Hypothesis and clues from an aflatoxin B1-exposed population. Cancer Sci 98: 140-146.
21. Brigelius-Flohe R, (1999) Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27: 951-965.
22. Mork H, Lex B, Scheurlen M, Dreher I, Schutze N, et al. (1998) Expression pattern of gastrointestinal selenoproteins-targets for selenium supplementation. Nutr Cancer 32: 64-70.
23. Tham DM, Whitin JC, Kim KK, Zhu SX, Cohen HJ, (1998) Expression of extracellular glutathione peroxidase in human and mouse gastrointestinal tract. Am J Physiol 275: G1463-G1471.
24. Foster CB, Aswath K, Chanock SJ, McKay HF, Peters U, (2006) Polymorphism analysis of six selenoprotein genes: support for a selective sweep at the glutathione peroxidase 1 locus (3p21) in Asian populations. BMC Genet 7: 56.
25. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120.
26. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
27. Chapman JM, Cooper JD, Todd JA, Clayton DG, (2003) Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power. Hum Hered 56: 18-31.
28. Steevens J, Schouten LJ, Driessen AL, Huysentruyt CJ, Keulemans YC, et al. (2010) Toenail selenium status and the risk of Barrett's esophagus: the Netherlands Cohort Study Cancer Causes Control 12: 2259-2268.
29. Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ, (2010) Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 138: 1704-1713.
30. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, et al. (1995) Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87: 497-505.
31. Longnecker MP, Stram DO, Taylor PR, Levander OA, Howe M, et al. (1996) Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 7: 384-390.
32. Duffield AJ, Thomson CD, Hill KE, Williams S, (1999) An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 70: 896-903.
33. Thomson CD, Robinson MF, Butler JA, Whanger PD, (1993) Long-term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. Br J Nutr 69: 577-588.
34. Blot WJ, McLaughlin JK, Fraumeni JF, (2006) Esophageal cancer. In: Schottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention New York Oxford University Press pp. 697-706.
35. Hansen RD, Krath BN, Frederiksen K, Tjonneland A, Overvad K, et al. (2009) GPX1 Pro(198)Leu polymorphism, erythrocyte GPX activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer. Mutat Res 664: 13-19.
36. Arsova-Sarafinovska Z, Matevska N, Eken A, Petrovski D, Banev S, et al. (2008) Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol 41: 63-70.
37. Ravn-Haren G, Olsen A, Tjonneland A, Dragsted LO, Nexo BA, et al. (2006) Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 27: 820-825.
38. Early DS, Hill K, Burk R, Palmer I, (2002) Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 97: 745-748.
39. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, et al. (2005) Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 7: 854-861.
40. Mork H, Scheurlen M, Al-Taie O, Zierer A, Kraus M, et al. (2003) Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus. Int J Cancer 105: 300-304.
41. Burk RF, Hill KE, (2005) Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 25: 215-235.
42. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, et al. (1999) Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein p. J Biol Chem 274: 2866-2871.
43. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, et al. (2011) Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 96: E1325-E1329.
44. Arteel GE, Briviba K, Sies H, (1999) Protection against peroxynitrite. FEBS Lett 445: 226-230.
45. Clemons NJ, McColl KE, Fitzgerald RC, (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133: 1198-1209.
46. McColl KE, (2005) When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 54: 1-3.
47. Clemons NJ, Shannon NB, Abeyratne LR, Walker CE, Saadi A, et al. (2010) Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. Carcinogenesis 31: 1669-1675.
48. Jimenez P, Piazuelo E, Sanchez MT, Ortego J, Soteras F, et al. (2005) Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J Gastroenterol 11: 2697-2703.